The US government should invest in a centralized government manufacturing facility that would be ready to quickly make biologics in the face of new health emergencies and pandemics, Regeneron Pharmaceuticals, Inc. leadership said on 18 November at the STAT Summit.
It’s an idea that was called for long before COVID-19. Regeneron’s Executive Vice President of Research and Development Neil Stahl testified about the idea to Congress in 2014 during the Ebola pandemic. The US has for some time done this for vaccines